Piper Sandler analyst John Barnidge downgraded MetLife (MET) to Neutral from Overweight with an unchanged price target of $84. The firm believes the shares are nearing fair value, trading less than 10% from the price target Many of MetLife’s catalysts are known at this time, like Chariot Re’s capabilities and the breaking out of the financials of MetLife Investment Management, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MET:
- MetLife Advises Against Potemkin’s Mini-Tender Offer
- Wolfe Research launches coverage with positive view on Life Insurance names
- MetLife recommends that shareholders reject mini-tender by Potemkin Limited
- MetLife initiated with an Outperform at Wolfe Research
- MetLife Announces Redemption of Preferred Stock Series G